Palliative Use of Inotropics in End-Stage Heart Failure

This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.

On average 1% of the population over 40 years of age acquires an initial stage of heart failure and this percentage doubles every 10 years, representing 10% in those over 70 years of age. This implies the great impact of the disease in relation to its incidence and prevalence; it currently affects more than 6 million adults in the United States, and 8 million patients are projected by 2030.Throughout the life of the heart failure patient it is usually necessary to apply a series of complex and invasive treatments, which however in advanced stages of the disease are less effective.A review of the American College of Cardiology / American Heart Association (ACC / AHA) Guidelines emphasizes palliative inotropic therapy as part of an overall plan to improve quality of life in this group of patients. This proposes a major challenge that diverts us from the main focus of these drugs; that is why through this review we propose that inotropic drugs would have a place as palliative treatment in end-stage heart failure.